SIGA Technologies (NASDAQ: SIGA) — Perfil da empresa, notícias e dados financeiros
SIGA Technologies specializes in antiviral solutions for biodefense, notably for smallpox.
SIGA Technologies
SIGA Technologies (NASDAQ:SIGA) specializes in the development and commercialization of solutions for serious unmet medical needs, particularly in the area of biodefense. The company's most notable project is their flagship product, an antiviral drug designed to treat smallpox, a critical component in the strategic national stockpile for biodefense against potential bioterror threats. By focusing on the rapid deployment of their antiviral solutions, SIGA aims to address both government and commercial needs worldwide, enhancing public health preparedness. Their objectives include expanding the applications of their antiviral technology to cover additional infectious diseases, securing further contracts with governmental agencies, and reaching out to new international markets to solidify their presence in global public health defense.
Resumo
Operações
Produtos e/ou serviços de SIGA Technologies
- TPOXX (tecovirimat), an oral formulation antiviral medication for the treatment of smallpox, approved by the FDA and a critical part of the strategic national stockpile.
- Intravenous (IV) formulation of tecovirimat, under development to provide an alternative administration route for patients unable to take oral medication.
- Expanded access program for tecovirimat, allowing its use for conditions caused by orthopoxviruses under specific regulatory guidelines beyond approved indications.
- Collaboration with government agencies for the development and stockpiling of antiviral agents against potential bioterrorism threats, enhancing biodefense capabilities.
- Participation in research studies and clinical trials to explore the efficacy of tecovirimat against emerging viral threats, contributing to global public health security.
- Engagement in partnerships for the distribution of TPOXX internationally, aiming to make the treatment accessible in markets outside the United States.
equipe executiva do SIGA Technologies
- Diem NguyenCEO & Director
- Daniel J. LuckshireExecutive VP, CFO & Secretary
- Dennis E. HrubyExecutive VP & Chief Scientific Officer
- Lawrence R. MillerGeneral Counsel & Corporate Secretary
- Herb VloedmanSenior VP & Chief Information Officer
- Suzanne HarnettSenior Vice President of Corporate Affairs & Investor Relations
Histórico de dividendos
Dividendos por ação pagos pela SIGA Technologies, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.6000 |
| FY2025 | — | — | — | $0.6000 |
| FY2024 | — | — | — | $0.6000 |
| FY2023 | — | — | — | $0.4500 |
| FY2022 | — | — | — | $0.4500 |
Principais indicadores financeiros
Resultados divulgados pela SIGA Technologies, em USD.
- Cap. de mercado
- 229,9 mi
- Receita (TTM)
- 53,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- 0.0%
- Margem de lucro
- -5.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 94,6 mi | 23,7 mi | 23,3 mi | |
| 138,7 mi | 70 mi | 59,2 mi | |
| 139,9 mi | 83,6 mi | 68,1 mi | |
| 110,8 mi | 42,7 mi | 33,9 mi |